Clinical Trial 23116

• Overview

  Study Title:

  IDE196 (Darovasertib) In Combination with Crizotinib Versus Investigators Choice of Treatment as First-Line Therapy In HLA-A2 Negative Metastatic Uveal Melanoma (Dar-Um-2)

• Treatments

  Therapies:

  Immunotherapy; Therapy (NOS)

  Medications:

  BMS-936558 (Nivolumab); Crizotinib (); IDE196 (); Ipilimumab (); Nivolumab (Opdivo); Pembrolizumab (Keytruda); Xalkori (Crizotinib); Yervoy (Ipilimumab)

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.